

**UNITED STATES OF AMERICA  
BEFORE THE FEDERAL TRADE COMMISSION**

**COMMISSIONERS:**      **Lina M. Khan, Chair  
Rebecca Kelly Slaughter  
Alvaro M. Bedoya**

**In the Matter of**

**Amgen Inc.,  
a corporation,**

**and**

**Horizon Therapeutics plc,  
a corporation,**

**Respondents.**

**DOCKET NO. 9414**

**PUBLIC**

**JOINT MOTION TO CONTINUE THE ADMINISTRATIVE HEARING  
UNTIL NOVEMBER 8, 2023**

Complaint Counsel and Respondents respectfully submit this Joint Motion to Continue the Administrative Hearing until November 8, 2023.

In light of the case management and scheduling order in the federal Section 13(b) proceeding, Complaint Counsel and Respondents request a short continuance of the start of the evidentiary hearing in the administrative proceeding (currently slated to begin on October 25, 2023) until November 8, 2023. The Section 13(b) evidentiary hearing (FTC v. Amgen Inc., No. 3:23-cv-03053 (N.D. Ill.)) is scheduled to take place in Chicago, Illinois between September 11-22, 2023, and post-hearing findings of fact and conclusions of law are due in that matter on September 29, 2023. At a status conference on May 23, 2023, the District Court expressed its intention to deliver by October 31, 2023, its ruling on the request for a preliminary injunction pursuant to Section 13(b).

Given that the federal court may rule in late October, and that Complaint or Respondents'

counsel may need to seek emergency appellate relief following the District Court's decision, the federal court proceeding presents conflicts in late October that would make it difficult for Complaint and Respondent counsel to begin the administrative hearing prior to November 8, 2023.

The parties thus request a short continuance of the start of the administrative hearing until November 8, 2023, which will enable the evidentiary hearing regarding the preliminary injunction to proceed before the administrative hearing, and avoid scheduling conflicts of counsel, while entailing only minimal delay in the administrative proceedings.

Dated: July 21, 2023

Respectfully submitted,

/s/ Nathan Brenner

Nathan Brenner  
Anjelica Sarmiento  
Federal Trade Commission  
600 Pennsylvania Ave., NW  
Washington, D.C. 20024

*Counsel Supporting the Complaint*

/s/ David R. Marriott

David R. Marriott  
dmarriott@cravath.com  
CRAVATH, SWAINE & MOORE LLP  
825 Eighth Avenue  
New York, New York 10019  
Telephone: (212) 474-1000  
Facsimile: (212) 474-3700

*Counsel for Respondent Amgen Inc.*

/s/ Ethan Glass

Ethan Glass  
eglass@cooley.com  
COOLEY LLP  
1299 Pennsylvania Avenue, NW, Suite  
700  
Washington, DC 20004  
Telephone: (202) 842-7800  
Facsimile: (202) 842-7899

*Counsel for Respondent Horizon  
Therapeutics plc*

**UNITED STATES OF AMERICA  
BEFORE THE FEDERAL TRADE COMMISSION**

**COMMISSIONERS:**      **Lina M. Khan, Chair  
Rebecca Kelly Slaughter  
Alvaro M. Bedoya**

**In the Matter of**

**Amgen Inc.,  
a corporation,**

**and**

**Horizon Therapeutics plc,  
a corporation,**

**Respondents.**

**DOCKET NO. 9414**

**[PROPOSED] ORDER ON JOINT MOTION TO CONTINUE  
THE ADMINISTRATIVE HEARING UNTIL NOVEMBER 8, 2023**

On July 21, 2023, the parties filed a joint motion to continue the administrative hearing. Accordingly,

**IT IS HEREBY ORDERED**, that the hearing in this proceeding is rescheduled to begin on November 8, 2023.

By the Commission.

\_\_\_\_\_  
April J. Tabor  
Secretary

ISSUED:

## CERTIFICATE OF SERVICE

I hereby certify that on July 21, 2023, I filed the foregoing document electronically using the FTC's E-Filing System, which will send notification of such filing to:

April Tabor  
Secretary  
Federal Trade Commission  
600 Pennsylvania Ave., NW, Rm. H-113  
Washington, DC 20580  
ElectronicFilings@ftc.gov

The Honorable D. Michael Chappell  
Administrative Law Judge  
Federal Trade Commission  
600 Pennsylvania Ave., NW, Rm. H-110  
Washington, DC 20580

I also certify that I caused the foregoing document to be served via email to:

David Marriott  
Timothy Cameron  
Daniel Zach  
Jesse Weiss  
Renata Hesse  
Samantha Hynes  
dmarriott@cravath.com  
tcameron@cravath.com  
dzach@cravath.com  
jweiss@cravath.com  
hesser@sullcrom.com  
hyness@sullcrom.com  
Cravath, Swaine & Moore LLP  
825 Eighth Avenue  
New York, NY 10019  
Sullivan & Cromwell LLP  
1700 New York Ave NW #700  
Washington, DC 20006

*Counsel for Respondent  
Amgen Inc.*

Ethan Glass  
Jacqueline Grise  
David Burns  
eglass@cooley.com  
jgrise@cooley.com  
dburns@cooley.com

Cooley LLP  
1299 Pennsylvania Avenue, NW  
Suite 700  
Washington, DC 20004-2400

*Counsel for Respondent  
Horizon Therapeutics plc*

Date: July 21, 2023

By: *s/Nathan Brenner*  
Nathan Brenner

*Counsel Supporting the Complaint*